Laboratoires Boiron, Segrate, Milan, Italy.
Ann Ist Super Sanita. 2012;48(1):105-9. doi: 10.4415/ANN_12_01_17.
The use of a complementary medicine approach, and specifically of the popular medicine Oscillococcinum, for the treatment of influenza-like syndromes remains controversial. This brief paper analyses the currently available literature on this homeopathic preparation and the Cochrane Collaboration's 2006 systematic review, along with other recent studies, in order to clarify certain fundamental aspects of its use in the treatment of influenza. In the light of the reported findings, and applying the rigorous criteria of evidence-based medicine, we suggest that this medicine should be placed in category "BI".
使用补充医学方法，特别是流行的顺势疗法药物 Oscillococcinum 来治疗流感样综合征仍然存在争议。本文简要分析了目前关于这种顺势疗法制剂的文献，以及 Cochrane 协作组 2006 年的系统评价和其他最近的研究，以阐明其在流感治疗中的某些基本方面。根据报告的研究结果，并应用循证医学的严格标准，我们建议将这种药物归入“BI”类别。
